The U.S. Food and Drug Administration (FDA) has expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used as a standalone treatment for millions of U.S. patients dealing with severe depression.

The post FDA Allows Use of J&J’s Ketamine-Derived Nasal Spray for Standalone Depression Treatment appeared first on Breitbart.